129 related articles for article (PubMed ID: 1341325)
1. Abnormal regulation of the myc gene in myeloid leukemia.
Gopal V; Kadam P; Preisler H; Hulette B; Li YQ; Steele P; Freeman J; Banavali S
Med Oncol Tumor Pharmacother; 1992; 9(3):139-47. PubMed ID: 1341325
[TBL] [Abstract][Full Text] [Related]
2. [Molecular analysis of transformation into blast crisis in chronic myelogenous leukemia].
Okabe M
Hokkaido Igaku Zasshi; 1993 Mar; 68(2):237-50. PubMed ID: 8509066
[TBL] [Abstract][Full Text] [Related]
3. Argininosuccinate synthetase gene expression in leukemias: potential diagnostic marker for blastic crisis of chronic myelocytic leukemia.
Ohno T; Kimura Y; Sakurada K; Sugimura K; Fujiyoshi T; Saheki T; Sonoda S; Azuma I
Leuk Res; 1992; 16(5):475-83. PubMed ID: 1625473
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the c-myc and N-ras genes in acute myelogenous leukemia cells which manifest the constitutive expression of the c-myc gene.
Kadam P; Steele P; Li YQ; Preisler H
Anticancer Res; 1993; 13(3):747-51. PubMed ID: 8317907
[TBL] [Abstract][Full Text] [Related]
5. Expression of the EVI1 gene in chronic myelogenous leukemia in blast crisis.
Russell M; Thompson F; Spier C; Taetle R
Leukemia; 1993 Oct; 7(10):1654-7. PubMed ID: 8412328
[TBL] [Abstract][Full Text] [Related]
6. Cytogenetic and molecular analysis of a "masked" Philadelphia chromosome in chronic and blastic phases of chronic myeloid leukemia.
Zitzelsberger H; Bauchinger M; Wilmanns W; Strauss PG
Cancer Genet Cytogenet; 1990 Jul; 47(2):219-25. PubMed ID: 2357696
[TBL] [Abstract][Full Text] [Related]
7. CML: mechanisms of disease initiation and progression.
Wetzler M; Talpaz M; Estrov Z; Kurzrock R
Leuk Lymphoma; 1993; 11 Suppl 1():47-50. PubMed ID: 8251916
[TBL] [Abstract][Full Text] [Related]
8. The role of c-Myc protooncogene in chronic myelogenous leukemia.
Nieborowska-Skórska M; Ratajczak MZ; Calabretta B; Skórski T
Folia Histochem Cytobiol; 1994; 32(4):231-4. PubMed ID: 7758616
[TBL] [Abstract][Full Text] [Related]
9. Detection of c-myc oncogene amplification in a CML blastic phase patient with double minute chromosomes.
Karasawa M; Okamoto K; Maehara T; Tsukamoto N; Morita K; Naruse T; Omine M
Leuk Res; 1996 Jan; 20(1):85-91. PubMed ID: 8632682
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes.
Ries C; Loher F; Zang C; Ismair MG; Petrides PE
Clin Cancer Res; 1999 May; 5(5):1115-24. PubMed ID: 10353746
[TBL] [Abstract][Full Text] [Related]
11. Expression of the myeloperoxidase gene in acute and chronic myeloid leukemias: relationship to the expression of cell cycle-related genes.
Ferrari S; Tagliafico E; Ceccherelli G; Selleri L; Calabretta B; Donelli A; Temperani P; Sarti M; Sacchi S; Emilia G
Leukemia; 1989 Jun; 3(6):423-30. PubMed ID: 2542700
[TBL] [Abstract][Full Text] [Related]
12. Experimental and integrative analyses identify an ETS1 network downstream of BCR-ABL in chronic myeloid leukemia (CML).
Desterke C; Voldoire M; Bonnet ML; Sorel N; Pagliaro S; Rahban H; Bennaceur-Griscelli A; Cayssials E; Chomel JC; Turhan AG
Exp Hematol; 2018 Aug; 64():71-83.e8. PubMed ID: 29733872
[TBL] [Abstract][Full Text] [Related]
13. Absence of N-ras mutations in myeloid and lymphoid blast crisis of chronic myeloid leukemia.
Watzinger F; Gaiger A; Karlic H; Becher R; Pillwein K; Lion T
Cancer Res; 1994 Jul; 54(14):3934-8. PubMed ID: 8033117
[TBL] [Abstract][Full Text] [Related]
14. Studies of proto-oncogene expression in the chronic and blastic phases of chronic myelogenous leukemia.
Preisler HD; Agarwal R; Sato H; Singh PK; Wang ZQ; Sandberg AA
Eur J Cancer; 1990; 26(9):960-5. PubMed ID: 2149022
[TBL] [Abstract][Full Text] [Related]
15. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.
Srutova K; Curik N; Burda P; Savvulidi F; Silvestri G; Trotta R; Klamova H; Pecherkova P; Sovova Z; Koblihova J; Stopka T; Perrotti D; Polakova KM
Haematologica; 2018 Dec; 103(12):2016-2025. PubMed ID: 30049824
[TBL] [Abstract][Full Text] [Related]
16. Proliferative advantage rather than classical drug resistance as the cause of treatment failure in chronic myelogenous leukemia.
Preisler HD; Raza A; Baccarani M
Leuk Lymphoma; 1993; 11 Suppl 1():303-6. PubMed ID: 7504547
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the p53 gene in patients with isochromosome 17q and Ph1-positive or -negative myeloid leukemia.
Schütte J; Opalka B; Becher R; Bardenheuer W; Szymanski S; Lux A; Seeber S
Leuk Res; 1993 Jun; 17(6):533-9. PubMed ID: 8505851
[TBL] [Abstract][Full Text] [Related]
18. Clinical and cytogenetic correlations of abnormal megakaryocytopoiesis in patients with acute leukemia and chronic myelogenous leukemia in blast crisis.
Lee EJ; Schiffer CA; Tomiyasu T; Testa JR
Leukemia; 1990 May; 4(5):350-3. PubMed ID: 2388480
[TBL] [Abstract][Full Text] [Related]
19. Interferon-alpha and bcr-abl antisense oligodeoxynucleotides in combination enhance the antileukemic effect and the adherence of CML progenitors to preformed stroma.
Bellucci R; Sala R; De Propris MS; Cordone I; de Fabritiis P
Leuk Lymphoma; 1999 Nov; 35(5-6):471-81. PubMed ID: 10609784
[TBL] [Abstract][Full Text] [Related]
20. An overview of some studies of chronic myelogenous leukemia: biological-clinical observations and viewing the disease as a chaotic system.
Preisler H; Raza A
Leuk Lymphoma; 1993; 11 Suppl 1():145-50. PubMed ID: 8251888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
